Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Current Assets (2019 - 2025)

Historic Current Assets for Volitionrx (VNRX) over the last 9 years, with Q3 2025 value amounting to $1.3 million.

  • Volitionrx's Current Assets fell 8041.33% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 8041.33%. This contributed to the annual value of $4.1 million for FY2024, which is 8143.69% down from last year.
  • According to the latest figures from Q3 2025, Volitionrx's Current Assets is $1.3 million, which was down 8041.33% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Volitionrx's Current Assets ranged from a high of $29.4 million in Q2 2021 and a low of $1.3 million during Q3 2025
  • For the 5-year period, Volitionrx's Current Assets averaged around $14.3 million, with its median value being $12.8 million (2023).
  • As far as peak fluctuations go, Volitionrx's Current Assets soared by 7954.19% in 2023, and later crashed by 8143.69% in 2024.
  • Over the past 5 years, Volitionrx's Current Assets (Quarter) stood at $22.0 million in 2021, then tumbled by 44.62% to $12.2 million in 2022, then skyrocketed by 79.54% to $21.9 million in 2023, then plummeted by 81.44% to $4.1 million in 2024, then plummeted by 67.16% to $1.3 million in 2025.
  • Its Current Assets stands at $1.3 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.3 million for Q1 2025.